secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTENSITY THERAPEUTICS, INC. (INTS)
CIK:        0001567264
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001567264-24-000042
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intensity Therapeutics doses first patient in Phase 3 sarcoma trial; cash $6.3M into Q1 2025
--------------------------------------------------------------------------------

- First patient dosed in Phase 3 INVINCIBLE-3 study of INT230-6 vs SOC in soft tissue sarcoma; plans 333 patients.
- Collaboration with SAKK for Phase 2 INVINCIBLE-4 study in early-stage triple-negative breast cancer; start Q3 2024.
- Net loss $5.0M in Q2 2024 vs $3.7M in Q2 2023; R&D expenses $3.6M (up from $0.9M).
- Cash, cash equivalents and marketable debt securities $6.3M as of June 30, 2024.
- Appointed Thomas Dubin, J.D., MPH to board of directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1567264/000156726424000042/0001567264-24-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1567264/000156726424000042/intensity-20240808.htm
  HTML page:      https://secwatch.observer/filing/0001567264-24-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer